The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system

International Journal of Molecular Sciences

Volumn 10, Issue 9, 2009, Pages 3776-3792

  Kyung, Taek Oh ^a   Hye, Jung Baik ^b   A, Hyeong Lee ^b   Young, Taik Oh ^c   Yu, Seok Youn ^d   Eun, Seong Lee ^b  

^a Chung Ang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Drug delivery system; Multi drug resistance; Nanoparticle; Tumor treatment

Indexed keywords

ABC TRANSPORTER; AMLODIPINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CERAMIDE; COPOLYMER; CYCLOSPORIN A; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELACRIDAR; FERRIC OXIDE; FOLIC ACID; GLIBENCLAMIDE; GLYCOPROTEIN P; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; POLOXAMER; TARIQUIDAR; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ANGIOGENESIS; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG TARGETING; DRUG UPTAKE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICELLE; MULTIDRUG RESISTANCE; PARTICLE SIZE; RECEPTOR BINDING; REVIEW; SOLID TUMOR; ULTRASOUND;

DRUG DELIVERY SYSTEM; MULTI-DRUG RESISTANCE; NANOPARTICLE; TUMOR TREATMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NANOCAPSULES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 70350169230     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms10093776     Document Type: Review

References (77)

1. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6, 688-701.
2. Berger, W.; Elbling, L.; Micksche, M. Chemoresistance of human malignant melanoma: Cellular and molecular aspects. Onkologie 1998, 21,105-110. (Pubitemid 28267628)
3. Minko, T.; Dharap, S.S.; Pakunlu, R.I.; Wang, Y. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 2004, 5, 389-406. (Pubitemid 38559349)
4. Crawford, J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat. Rev. 2002. 28, 7-11. (Pubitemid 34679212)
5. Kim, R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005, 103, 1551-1560. (Pubitemid 40490015)
6. Wardwell, N.R.; Massion, P.P. Novel strategies for the early detection and prevention of lung cancer. Semin. Oncol. 2005, 32, 259-268. (Pubitemid 40834482)
7. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transports. Nat. Rev. Cancer 2000, 2, 48-58.
8. Thomasand, H.; Coley, H.M. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003, 10, 159-165.
9. Choi, C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005, 5, 30-42.
10. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
11. Ferrari, M.; Barker, A; Downing, G. A cancer nanotechnology strategy. NanoBioTechnology 2005, 1, 129-131.
12. Gillies, E.R.; Frechet, J.M. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. 2005, 16, 361-368.
13. Heath, J.R.; Davis, M.E. Nanotechnology and cancer. Annu. Rev. Med. 2008, 59, 251-265.
14. Ozben, T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006, 580, 2903-2909. (Pubitemid 43729172)
15. Simon, S.; Schindler, M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA 1994, 91, 3497-3504. (Pubitemid 24139457)
16. Gottesman, M.M. Mechanisms of cancer drug resistance. Ann. Rev. Med. 2002, 53, 615-627.
17. Leith, C.P.; Kopecky, K.J.; Chen, I.M.; Eijdems, L.; Slovak, M.L.; McConnell, T.S.; Head, D.R.; Weick, J.; Grever, M.R.; Appelbaum, F.R.; Willman, C.L. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A southwest oncology group study. Blood 1999, 94, 1086-1099.
18. van der Zee, A.G.; Hollema, H.; Suurmeijer, A.J.; Krans, M.; Sluiter, W.J.; Willemse, P.H.; Aalders, J.G.; de Vries, E.G. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 1995, 13, 70-78.
19. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11, 1156-1166. (Pubitemid 32677289)
20. Leonard, G.D.; Fojo, T.; Bates, S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411-424. (Pubitemid 37238869)
21. Fardel, O.; Lecureur, V.; Guillouzo, A. The P-glycoprotein multidrug transporter. Gen. Pharmac. 1996, 27, 1283-1291.
22. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A Family of drug transporters: The multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302. (Pubitemid 30662093)
23. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670. (Pubitemid 29018757)
24. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochim. 1993, 62, 385-1361 (Pubitemid 23237876)
25. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
26. Scheffer, G.L.; Wijngaard, P.L.J.; Flens, M.J.; Izquierdo, M.A.; Slovak, M.L.; Pinedo, H.M.; Meijer, C.J.L.M.; Clevers, H.C.; Scheper, R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1995, 1, 578-582.
27. Izquierdo, M.A.; Shoemaker, R.H.; Flens, M.J.; Scheffer, G.L.; Wu, L.; Prather, T.R.; Scheper, R.J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer 1996, 65, 230-237. (Pubitemid 26051685)
28. Yang, H.H.; Ma, M.H.; Vescio, R.A.; Berenson, J.R. Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J. Clin. Oncol. 2003, 21, 4239-4247.
29. Hickman, J.A. Apoptosis and chemotherapy resistance. Eur. J. Cancer 1996, 32A, 921-926.
30. Bushand, J.A.; Li, G. Cancer chemoresistance: The relationship between p53 and multidrug transporters. Int. J. Cancer 2002, 98, 323-330. (Pubitemid 34188673)
31. Kannan, K.; Kaminski, N.; Rechavi, G.; Jakob-Hirsch, J.; Amariglio, N.; Givol, D. DNA microarray analysis of genes involved in p53 mediated apoptosis: Activation of Apaf-1. Oncogene 2001, 20, 3449-3455. (Pubitemid 32588994)
32. Fisher, D.E. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994, 78, 539-542. (Pubitemid 24268576)
33. Matsuo, K.; Kohno, K.; Takano, H.; Sato, S.; Kiue, A.; Kuwano, M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer kb cell lines. Cancer Res. 1990, 50, 5819-5824. (Pubitemid 20331383)
34. Minchinton, A.I.; Tannock, I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6, 583-592.
35. Frazier, M.C.; Simons, J.W.; Zhong, H.; Mabjeesh, N.J. Hypoxia-directed cancer therapy. Expert Opin. Ther. Pat. 2002, 12, 777-788.
36. Zhou, J.; Schmid, T.; Schnitzer, S.; Brune, B. Tumor hypoxia and cancer progression. Cancer Lett. 2006, 237, 10-21.
37. Chakravarti, A.; Loeffler, J.S.; Dyson, N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002, 62, 200-207.
38. Konig, A.; Menzel, T.; Lynen, S.; Wrazel, L.; Rosen, A.; Al-Katib, A.; Raveche, E.; Gabrilove, J.L. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997, 11, 258-265.
39. Wang, X.W.; Yeh, H.; Schaeffer, L.; Roy, R.; Moncollin, V.; Egly, J.M.; Wang, Z.; Friedberg, E.C.; Evans, M.K.; Taffe, B.G.; Bohr, V.A.; Weeda, G.; Hoeijmakers, J.H.J.; Forrester, K.; Harris, C.C. P53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 1995, 10, 188-193.
40. Hofmann, C.; Obermeier, F.; Artinger, M.; Hausmann, M.; Falk, W.; Schoelmerich, J.; Rogler, G.; Grossmann, J. Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology 2007, 132, 587-600. (Pubitemid 46274657)
41. Shain, K.H.; Dalton, W.S. Cell adhesion is a key determinant in de novo multidrug resistance (mdr): New targets for the prevention of acquired MDR. Mol. Cancer Ther. 2001, 1, 69-78.
42. Mahadevan, D.; List, A.F. Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies. Blood 2004, 104, 1940-1951.
43. Fox, E.; Bates, S.E. Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 2007, 7, 447-459.
44. Golstein, P.E.; Boom, A.; van Geffel, J.; Jacobs, P.; Masereel, B.; Beauwens, R. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999, 437, 652-660. (Pubitemid 29161920)
45. Advani, R.; Lum, B.L.; Fisher, G.A.; Halsey, J.; Chin, D.L.; Jacobs, C.D.; Sikic, B.I. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann. Oncol. 2005, 16, 1968-1973.
46. Dantzig, A.H.; Shepard, R.L.; Cao, J.; Law, K.L.; Ehlhardt, W.J.; Baughman, T.M.; Bumol, T.F.; Starling, J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996, 56, 4171-4179. (Pubitemid 26305012)
47. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridone carboxamide derivative. Cancer Res. 1993, 53, 4595-4602. (Pubitemid 23304385)
48. Ferry, D.R.; Traunecker, H.; Kerr, D.J. Clinical trials of P-glycoprtoein reversal in solid tumours. Eur. J. Cancer 1996, 31A, 1070-1081. (Pubitemid 26192988)
49. Mahadevan, D.; List, A.F. Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies. Blood 2004, 104, 1940-1951.
50. Kabanov, A.V.; Alakhov, V.Y. Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19, 1-72.
51. Kabanov, A.V.; Batrakova, E.V.; Alakhov, V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 2002, 54, 759-779.
52. Batrakova, E.; Lee, S.; Li, S.; Venne, A.; Alakhov, V.; Kabanov, A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in mdr cancer cells. Pharm. Res. 1999, 16, 1373-1379. (Pubitemid 29449373)
53. 2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J. Control. Release 2006, 112, 186-198.
54. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207. (Pubitemid 32520323)
55. Bergstrand, N.; Edwards, K. Effects of poly(ethylene oxide)- poly(propylene oxide)-poly(ethylene oxide) triblock copolymers on structure and stability of liposomal dioleoylphosphatidylethanolamine. J. Colloid Interface Sci. 2004, 276, 400-407. (Pubitemid 38951001)
56. Wang, J.C.; Liu, X.Y.; Lu, W.L.; Chang, A.; Zhang, Q.; Goh, B.C.; Lee, H.S. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur. J. Pharm. Biopharm. 2006, 62, 44-51.
57. Deng, W.J.; Yang, X.Q.; Liang, Y.J.; Chen, L.M.; Yan, Y.Y.; Shuai, X.T.; Fu, L.W. FG020326- loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo. Acta Pharmacol. Sin. 2007, 28, 913-920.
58. Pakunlu, R.I.; Wang, Y.; Saad, M.; Khandare, J.J.; Starovoytov, V.; Minko, T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release 2006, 114, 153-162. (Pubitemid 44291853)
59. Poupaert, J.H.; Couvreur, P. A computationally derived structural model of doxorubicin interacting with oligomeric polyalkylcyanoacrylate in nanoparticles. J. Control. Release 2003, 92, 19-26. (Pubitemid 37130118)
60. Soma, C.E.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21, 1-7.
61. Lu, D.; Wientjes, M.G.; Lu, Z.; Au, J.L. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 2007, 322, 80-88.
62. van Vlerken, L.E.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007, 67, 4843-4850.
63. Rapoport, N. Combined cancer therapy by micellar-encapsulated drug and ultrasound. Int. J. Pharm. 2004, 277, 155-162. (Pubitemid 38670430)
64. Gao, Z.; Fain, H.D.; Rapoport, N. Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol. Pharm. 2004, 1, 317-330.
65. Yongzhong, W.; Li, Y.; Limei, H.; Xianyi, S.; Xiaoling, F. Difunctional pluronic copolymer micelles for paclitaxel delivery: Syngergistic effect of folate-mediated targeting and pluronicmediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm. 2007, 337, 63-73.
66. Kim, D.; Lee, E.S.; Oh, K.T.; Gao, Z.G.; Bae, Y.H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008, 4, 2043-2050.
67. Kobayashi, T.; Ishida, T.; Okada, Y.; Ise, S.; Harashima, H.; Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in p-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 2007, 329, 94-102. (Pubitemid 44937528)
68. Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 2000, 6, 1949-1957. (Pubitemid 30305094)
69. Lee, E.S.; Na, K.; Bae, Y.H. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 2003, 91, 103-113.
70. Lee, E.S.; Oh, K.T.; Kim, D.; Youn, Y.S.; Bae, Y.H. Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L- histidine). J. Control. Release 2007, 123, 19-26.
71. Lee, E.S.; Na, K.; Bae, Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 2005, 103, 405-418.
72. Lee, E.S.; Na, K.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 2005, 5, 325-329.
73. Lee, E.S.; Gao, Z.; Kim, D.; Park, K.; Kwon, I.C.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Control. Release 2008, 129, 228-236.
74. Lewin, M.; Carlesso, N.; Tun, C.H.; Tang, X.W.; Cory, D.; Scadden, D.T.; Weissleder, R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 2000, 18, 410-414. (Pubitemid 30217528)
75. Lee, E.S.; Kim, D.; Youn, Y.S.; Oh, K.T.; Bae, Y.H. A virus-mimetic nanogel vehicle13. Angew. Chem. Int. Ed. 2008, 47, 2418-2421.
76. Lee, E.S.; Gao, Z.; Bae, Y.H. Recent progress in tumor pH targeting nanotechnology. J. Control. Release 2008, 132, 164-170.
77. Boussif, O.; Lezoualc'h, F.; Zanta, M.A.; Merqny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonnucleotide transfer into cells in culture and in vivo: Polyethyleneimine. Proc. Natl. Acad. Sci. USA 1995, 92, 7297-7301.